EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieMultizentrische StudieRandomisierte kontrollierte StudieOpen Access

Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer

Elske C Gootjes, Lotte Bakkerus, Anviti A Adhin, Barbara M Zonderhuis, Kathelijn S Versteeg, Jurriaan B Tuynman, Martijn R Meijerink, Cornelis J A Haasbeek, Johannes H W de Wilt, Dirk J Grunhagen, Ewoud J Smit, John M Primrose und 9 weitere

JAMA · 21.04.2026 · 335 (15) · 1311

DOI: 10.1001/jama.2026.1929 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift JAMA, erschienen am 21.04.2026. Verfasst von Elske C Gootjes und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Cytoreduction Surgical Procedures, Palliative Care. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Local therapy, including surgery, radiation, and ablation, is increasingly used in patients with multiorgan metastatic colorectal cancer (mCRC). However, prospective evidence for a survival benefit of tumor debulking is lacking.

Objective

To investigate whether tumor debulking added to palliative chemotherapy improves survival of patients with multiorgan mCRC. Design, Setting, and Participants This investigator-initiated, open-label, multicenter, randomized clinical trial enrolled patients with multiorgan mCRC between May 2013 and May 2023. The last date of follow-up was April 4, 2024. Patients were enrolled in 27 hospitals in the Netherlands and 1 in the UK. Adult patients with multiorgan mCRC were considered eligible if more than 80% tumor debulking was deemed feasible by resection, radiotherapy, and/or thermal ablation prior to starting first-line palliative chemotherapy.

Interventions

After achieving objective tumor response or stable disease after 3 cycles of capecitabine and oxaliplatin or 4 cycles of 5-fluorouracil and oxaliplatin with or without bevacizumab, patients were randomized 1:1 to receive chemotherapy alone (standard care group) or tumor debulking followed by chemotherapy. Main Outcomes and Measures The primary end point was overall survival. Secondary end points included progression-free survival and serious adverse events. These outcomes were analyzed in the intention-to-treat population, applicable from randomization. A prespecified interim analysis performed after the initial 100 participants were enrolled revealed that the trial was both safe and feasible to proceed.

Results

A total of 382 of 454 enrolled patients were randomized: 192 in the chemotherapy alone group (133 [69%] male) and 190 in the chemotherapy plus tumor debulking group (127 [67%] male). The median age was 64 years in both groups. After a median follow-up of 32.3 months, median overall survival in the chemotherapy alone group was 27.5 months vs 30.0 months in the chemotherapy plus tumor debulking group (adjusted hazard ratio, 0.88 [95% CI, 0.70-1.10]; P = .26). Median progression-free survival in the chemotherapy alone group was 10.4 months vs 10.5 months in the chemotherapy plus tumor debulking group (adjusted hazard ratio, 0.83 [95% CI, 0.67-1.02]; P = .08). More patients in the chemotherapy plus tumor debulking vs chemotherapy alone group had any serious adverse events (101 [53%] vs 74 [39%]; P = .006). Conclusions and Relevance Tumor debulking in addition to first-line palliative systemic treatment failed to improve overall survival compared with systemic treatment alone for patients with multiorgan mCRC and should not be considered standard care. Trial Registration ClinicalTrials.gov Identifier: NCT01792934

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsCytoreduction Surgical ProceduresPalliative CareChemotherapy, AdjuvantAdultAgedFemaleHumansMaleMiddle AgedBevacizumabCapecitabineFluorouracilOxaliplatinAblation TechniquesFollow-Up StudiesProgression-Free SurvivalYoung Adult

Substanzen

BevacizumabCapecitabineFluorouracilOxaliplatin

Autor:innen und Institutionen

  • Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, the Netherlands.
  • Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
  • Department of Medical Oncology, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
  • Department of Radiology and Nuclear Medicine, Amsterdam UMC, Amsterdam, the Netherlands.
  • Department of Radiotherapy, Cancer Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.

Zitieren

APA

Gootjes, E. C., Bakkerus, L., Adhin, A. A., Zonderhuis, B. M., Versteeg, K. S., Tuynman, J. B., Meijerink, M. R., Haasbeek, C. J. A., de Wilt, J. H. W., Grunhagen, D. J., Smit, E. J., Primrose, J. M., Bridgewater, J., van Meerten, E., de Groot, J. B., Hendriks, M. P., Oomen-de Hoop, E., Buffart, T. E., Verhoef, C., …, & ORCHESTRA Study Group (2026). Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer. JAMA, 335(15), 1311. https://doi.org/10.1001/jama.2026.1929

Vancouver

Gootjes EC, Bakkerus L, Adhin AA, Zonderhuis BM, Versteeg KS, Tuynman JB, et al. Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer. JAMA. 2026;335(15):1311. doi:10.1001/jama.2026.1929

BibTeX
@article{Gootjes2026,
  author = {Gootjes, Elske C and Bakkerus, Lotte and Adhin, Anviti A and Zonderhuis, Barbara M and Versteeg, Kathelijn S and Tuynman, Jurriaan B and Meijerink, Martijn R and Haasbeek, Cornelis J A and de Wilt, Johannes H W and Grunhagen, Dirk J and Smit, Ewoud J and Primrose, John M and Bridgewater, John and van Meerten, Esther and de Groot, Jan-Willem B and Hendriks, Mathijs P and Oomen-de Hoop, Esther and Buffart, Tineke E and Verhoef, Cornelis and Verheul, Henk M W and ORCHESTRA Study Group, ORCHESTRA Study Group},
  title = {Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer},
  journal = {JAMA},
  year = {2026},
  volume = {335},
  number = {15},
  pages = {1311},
  doi = {10.1001/jama.2026.1929}
}
Kostenlos starten →